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ABSTRACT Human P-globin mRNAs truncated in the
second exon or in the first intron have been processed in vitro
in a HeLa cell nuclear extract. Transcripts containing a
fragment of the second exon as short as 53 nucleotides are
efficiently spliced, whereas transcripts truncated 24 or 14
nucleotides downstream from the 3' splice site are spliced
inefficiently, if at all. AU of these transcripts, however, are
efficiently and accurately cleaved at the 5' splice site. In
contrast, RNA truncated in the first intron, 54 nucleotides
upstream from the 3' splice site, is not processed at all. These
findings suggest that cleavage at the 5' splice site and subse-
quent splicing steps-i.e., cleavage at the 3' splice site and exon
ligation-need not be coupled. Anti-Sm serum inhibits the
complete splicing reaction and cleavage at the 5' splice site,
suggesting involvement of certain ribonucleoprotein particles
in the cleavage reaction. ATP and Mg2' are required for
cleavage at the 5' splice site at concentrations similar to those
for the complete splicing reaction.
Recently, several systems for in vitro splicing of eukaryotic
mRNA have been developed. The early systems relied either
on coupled transcription and splicing ofmRNA transcripts in
whole cell extracts from HeLa cells (1-3) or on the addition
of exogenous precursor mRNA to whole cell extracts from
HeLa cells (4) or to nuclear extracts from MOPC-315 cells (5,
6). Progress was slow due to the inefficiency of the splicing
extracts and the limited availability of substrate RNA. The
recent development of a highly efficient nuclear splicing
extract (7, 8) and the methods to transcribe large amounts of
precursor RNA from DNA templates cloned under the SP6
promoter (9, 10) led to rapid advances in this field.
The steps in mRNA splicing, formulated by recent in vitro
studies (refs. 11-16; see ref. 17 for a recent review), appear
to be as follows: a capped RNA transcript is cleaved at the
5' splice site and, simultaneously, the first nucleotide of the
intron attacks an adenosine residue located 20-40 nucleo-
tides (nt) upstream from the 3' splice site, forming a lariat
structure. This lariat intermediate is then cleaved at the 3'
splice site with concomitant ligation of the 5' exon, thus
generating a spliced mRNA and the free intron in the lariat
form. The details of the phosphodiester bond formation
during splicing have been determined (13) and the participa-
tion of U1 ribonucleoprotein (U1-RNP) in the splicing reac-
tion has been convincingly shown (18-21).
In spite of this remarkable progress, many aspects of the
splicing reaction are still poorly understood. The mechanisms
of splice site selection and alternative splicing are unknown
as are the properties of the partially purified splicing enzymes
(22). The events that occur during a pronounced initial lag
period that is observed in vitro (7) as well as the properties of
and relationship among the subsequent splicing steps have
not been analyzed in detail.
Although several sequence elements are known to be
essential for splicing [splice site consensus sequences,
polypyrimidine stretch, branch point (17)], it is not known if
exon sequences play any role in splicing. It could be expected
that exon sequences contribute to the overall structure of the
precursor RNA that is necessary for splicing. We have
addressed this problem by studying in vitro splicing ofhuman
f3-globin mRNA precursor transcripts that have been sys-
tematically truncated within the second exon of the globin
gene. The results reported hereshow that transcripts missing
most but not all of the second exon sequences are not spliced
but are only cleaved at the 5' splice site.
MATERIALS AND METHODS
DNA templates were prepared by linearizing the plasmid
pSP64HbA6 (7) with restriction enzymes that cleave within
the second exon and the first intron of the human P-globin
gene (see Fig. 1).
Transcription and capping of the substrate RNA was
carried out essentially as described by Konarska et al. (14).
In vitro splicing reactions were performed at 30'C for 2 hr in
a 25-tlI reaction mixture with 5 mM ATP, 3.3 mM MgCl2, 20
mM creatine phosphate, 2.6% polyvinyl alcohol, 60% HeLa
cell nuclear extract, and [32P]RNA (7, 8). [32P]RNA products
from in vitro processing reactions were electrophoresed on a
5% polyacrylamide sequencing gel (23) and autoradio-
graphed. For more detailed analysis, the products from 30
reaction mixtures were pooled and separated on several gels.
The appropriate bands were eluted, digested with RNase T1
(5 units of the enzyme in a 5-,ul reaction mixture in 10 mM
Tris'HCl, pH 7.5/1 mM EDTA buffer) for 20 min at 37°C, and
analyzed further on a 20% polyacrylamide sequencing gel.
Alternatively, some RNAs were analyzed by a standard
two-dimensional fingerprinting procedure (24).
Inhibition of the processing reactions was carried out by
incubating 15 Al of the nuclear extract with 1 u.l of a purified
IgG fraction (5-15 mg of protein per ml) of sera from patients
with systemic lupus erythematosus (SLE) for 30 min at 0°C.
The IgG fractions were prepared as described (25) and
dialyzed against 10 mM Tris HCl, pH 7.5/10 mM NaCl. The
pretreated extract was then used in the splicing reaction
under standard conditions.
RESULTS
Processing of Human (-Globin mRNA Truncated in the
Second Exon. We have used a HeLa cell nuclear splicing
extract (7, 8) to study processing of a series of RNA
transcripts terminating within the second exon of the human
3-globin gene (Fig. 1). The longest transcript, terminating at
the BamHI site within the second exon, gave rise to four
Abbreviations: RNP, ribonucleoprotein; snRNP, small nuclear
RNP; SLE, systemic lupus erythematosus; nt, nucleotide(s).
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FIG. 1. Structure of the RNA transcripts and the DNA template from human f3-globin gene. The top diagram represents a fragment of the
DNA template, derived from a human f3-globin gene cloned under the SP6 promoter (plasmid pSP64HbA6). The template was linearized with
indicated restriction enzymes and used for in vitro transcription with SP6 polymerase. The transcribed RNAs, which are truncated at the
appropriate restriction sites, are diagrammed below. Open boxes, exons; open box labeled SP6, SP6 promoter; thin lines, introns and
untranslated region. The asterisk indicates the branch point of the lariat structure. The numbers next to the transcripts indicate nucleotide length
of the transcript. The numbers inside the exons indicate the distance (in nucleotides) from the 3' splice site to the 3' end of the transcript. The
distance from the 5' end of the transcript to the 5' splice site is 154 nt.
prominent products in addition to the unprocessed input
RNA (Fig. 2, lane 1). Ruskin et al. (12) characterized these
products and showed them to be the intron in the lariat form
attached to the second exon, spliced mRNA, 5'-proximal
sequences containing the 5' exon, and the excised intron (Fig.
2, lane 1, bands b-e, respectively). We have analyzed all of
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FIG. 2. In vitro splicing of the truncated human ,B-globin mRNA
precursors. RNA transcribed and processed as described in the text
was isolated and analyzed on a 5% polyacrylamide sequencing gel.
Restriction enzymes used to linearize and truncate the DNA template
are indicated at the top. The length in nucleotides of each of the
transcripts and ofthe 5' fragment is shown on the right. The structure
of the RNA in bands a-e (lane 1) is indicated on the left. a, input
RNA; b, 3' half carrying the intron in the lariat form; c, the spliced
product; d, 5' fragment containing the first exon and 5' untranslated
sequence; e, released intron in the lariat form. Additional minor
bands in lane 1 are most likely unspecific degradation products.
found that the gel pattern of the digests was consistent with
the expected sequences of the respective RNAs. Moreover,
bands b and e exhibited aberrant mobility on polyacrylamide
gels of different porosity, a feature characteristic of lariat
structures (results not shown; see also Fig. 4).
Lanes 2-5 in Fig. 2 show the results of processing RNA
run-off products terminating 162 (Ban I), 53 (Sau3AI), 24
(Ava II), and 14 (Acc I) nt downstream from the 3' splice site.
These transcripts, when processed in the splicing extract,
each gave rise to a band comigrating with the 5' exon (band
d), indicating that cleavage at the 5' splice site occurred
efficiently regardless of the length of the substrate. Tran-
scripts in lanes 2 and 3 also generated band e as a prominent
product, which has the mobility of the free intron in the lariat
form when electrophoresed on the 5% (Fig. 2, lanes 1-3) and
8% (not shown) polyacrylamide sequencing gels. Quantita-
tion of band e in each lane by scintillation spectroscopy
indicates that this product is generated in comparable
amounts during processing of all three transcripts. Since this
product is diagnostic for the ligation step in the splicing
reaction (11-17), it is likely that the transcripts truncated 162
and 53 nt downstream from the 3' splice site are spliced as
efficiently as the longest transcript. We have not analyzed the
other bands that are seen in lanes 2 and 3 but their numbers
and their mobilities on the gel suggest that they are the
expected products and intermediates of splicing. First, there
is a band in each lane that migrates as exon 1 (band d, lane
1). Second, there is a band whose mobility on the gel is
consistent with the expected size of the spliced product (316
nt for Ban I and 207 nt for Sau3AI).
Transcripts terminating 24 and 14 nt downstream from the
3' splice site were spliced very inefficiently, if at all. This is
shown by the trace amounts or complete lack of the free
intron, band e, in lanes 4 and 5 (Fig. 2). Although these
transcripts are not effectively spliced, the band that comi-
grates with band d, lane 1, is produced in large amounts. The
analysis of this band from lane 5 is shown below.
Fig. 2, lane 6, shows the results of processing a transcript
that terminates within the intron, 54 nt upstream from the 3'
splice site. Under normal splicing conditions, this transcript
was not processed at all. Since it lacks the 3' splice site, the
absence of a spliced product was expected. However, the
absence of a band containing the 5' exon (band d) indicates
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that cleavage at the 5' splice site was also prevented,
suggesting that the RNA sequence missing in this transcript
plays a role in cleavage at the 5' splice site (see Discussion).
Analysis of the Cleavage Products. From the results pre-
sented in Fig. 2, lane 5, it appears that during processing of
the transcript terminating 14 nt downstream from the 3' splice
site no spliced product is generated. The only product that is
visible is a band comigrating with the 5' exon. If this band is
produced by cleavage at the 5' splice site, one would also
expect to see a 3' half of the molecule containing the intron
and 14 nt ofthe second exon. Since the 3' half of the molecule
could be in the lariat form (11, 12), it may have aberrant
mobility and comigrate with the 5' exon on the 5% polyacryl-
amide sequencing gel. To identify the RNA in this band, the
material was eluted from the gel and electrophoresed on a
12% polyacrylamide sequencing gel. Under these conditions,
the material separated into two bands, one with the mobility
ofthe 5' exon (Fig. 3A, lane 2, band d) and the other migrating




the RNA in the latter band has an unusual mobility, it is most
likely the 3' half of the molecule, consisting of the intron in
the lariat form and the 14 nt of the second exon.
To analyze these products in more detail and to ascertain
that the cleavage occurred exactly at the 5' splice site, we
have treated the RNAs from bands b and d (Fig. 3A, lane 2)
with RNase T1 and analyzed the products of digestion on a
20% polyacrylamide sequencing gel. Analysis of band d (Fig.
3B, lane 3) showed that this RNA contained all of the large
oligonucleotides characteristic of the 5' exon (the 13-mer, a
10-mer, and the 9-mer; see Fig. 3D). In addition, a band was
present that was not found in an RNase T1 digest of the
unprocessed run-off transcript (Fig. 3B, lane 2) and that
comigrated with the trinucleotide CAG (CAGOH, Fig. 3B,
lane 4). The RNase T1 digest of the unprocessed transcript
generates CAGp, a unique trinucleotide located at the 5'
splice junction (see Fig. 3D). Therefore, CAG trinucleotide
could be generated in an RNase T1 digest of band d only if
cleavage during splicing of the precursor RNA occurred
C






















FIG. 3. Analysis of the products generated by cleavage at the 5' splice site. (A) Analysis of the cleavage products on a 12% polyacrylamide
gel. Lane 1, RNA transcribed from the Acc I truncated template and processed as above (see Fig. 2, lane 5). Lane 2, RNA isolated from band
d (Fig. 2, lane 5), reanalyzed on 12% gel. The sizes of the input RNA and of the cleavage products are shown on the right. Asterisk indicates
the abnormal mobility of the lariat-containing fragment. The structure of the products is shown on the left. The small open box represents 14
nt of the second exon. (B) Analysis of the fragment containing the 5' exon by RNase T1 digestion. RNA eluted from band d (A, lane 2) was
digested with RNase T1 and analyzed on a 20% polyacrylamide sequencing gel. For comparison, input RNA-i.e., the transcript truncated 14
nt downstream from the 3' splice site-was treated in the same manner. CAGp, used as a marker, was isolated from the appropriate spot in
the fingerprint of the input RNA. CAG (CAGoH) was obtained by treatment of the CAGp trinucleotide with alkaline phosphatase. Lane 1, CAGp
trinucleotide. Lane 2, RNase T1 digest of the input RNA (band a, A, lane 1). Lane 3, RNase T1 digest of the 5' exon-containing fragment (band
d, A, lane 2). Lane 4, CAG trinucleotide. Numbers indicate the lengths of the characteristic oligonucleotides. (C) Analysis of the 3' half of the
molecule that contains the intron in the lariat form. Material eluted from band b (A, lane 2) was analyzed as in B. Lane 1, CAGp. Lane 2, input
RNA. Lane 3, 3' half of the molecule; a new oligonucleotide not present in the inputRNA is indicated by the arrow. Lane 4, CAG. (D) Sequence
of the RNA transcribed from the Acc I truncated template. Untranslated and exon sequences are in uppercase letters; intron is in lowercase
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exactly at the 5' splice site between the first guanosine and
the 5' phosphate group: ...GpGpCpApG/pGpUpUpGp....
Cleavage by splicing enzyme(s) at any other position would
generate a trinucleotide CAGp, which migrates in a different
position on the gel (Fig. 3B, lane 1). Therefore, it can be
concluded that in the nuclear extract, the cleavage reaction
that produced band d occurred exactly at the 5' splice site,
resulting in a 5' exon with a hydroxyl group at its 3' end, in
agreement with similar observations by Padgett et al. (13).
Fig. 3C shows an analysis of the RNA eluted from band b
(Fig. 3A). This RNA lacked all of the oligonucleotides
discussed above but contained a unique 19-mer that is located
within the intron adjacent to the 3' splice site (Fig. 3C, lane
3). A 10-mer, which should be present if this RNA contained
the intron, appeared to have the approximate mobility of an
1i-mer. The altered mobility of the 10-mer is expected for an
RNA containing the lariat structure before RNase T1 diges-
tion because the 10-mer should contain the branch point, an
additional guanosine residue attached by a 2',5'-phosphodi-
ester bond to the adenosine residue of the oligonucleotide
(indicated by the asterisk in the sequence in Fig. 3D). The
aberrant mobility of the RNA from band b on sequencing
polyacrylamide gels of different porosities and the analysis of
its RNase T1 digestion products strongly suggest that this
RNA is the 3' half of the cleaved molecule containing 14 nt
of the second exon and the intron in the lariat form.
Characteristics of the 5' Splice Site Cleavage Reaction. The
requirements of the cleavage reaction at the 5' splice site
(using the run-off transcript terminating 14 nt downstream
from the 3' splice site) compared to those of the complete
splicing reaction (using the transcript with 209 nt of the
second exon) appear to be very similar (4, 7). In particular,
both ATP and Mg2+ are required for cleavage and the
concentration optima for these cofactors are the same as in
the splicing reaction [0.5 mM for ATP and 3 mM for Mg2+
(data not shown)]. Similar to splicing, cleavage at the 5' splice
site has a temperature optimum at 30'C (data not shown).
The time course of the 5' splice cleavage reaction under
optimal conditions is presented in Fig. 4. A lag of about 30
mn, which is normally seen during the splicing reaction (7,
11-15), was also observed (Fig. 4, lane 2). During this time,
all breakdown products present in the input RNA (Fig. 4, lane
1) were completely degraded. The correct cleavage products
started to appear after 30 min and continued to accumulate
for 2 hr (Fig. 4, lanes 3-5). This result suggests that any
aberrant RNA products are selectively destroyed by
nucleases while the intermediates of the splicing reaction are
protected from degradation. After 4 hr, a portion of the input
RNA and the 5' splice site cleavage products have been
degraded in this experiment (Fig. 4, lane 6); however, in other
experiments, the degradation at this time point was not
pronounced.
Inhibition of Cleavage and Splicing by Antisera to Small
Nuclear RNPs (snRNPs). Sera from patients with SLE, which
contain autoantibodies with anti-Sm and anti-Ul-RNP spec-
ificity, inhibit the splicing reaction (18, 20). These autoanti-
bodies are directed against snRNP particles (26) and presumn-
ably block correct interactions of U1-RNP and/or other
snRNPs with the rest of the splicing machinery and with the
substrate RNA. There is evidence that U1-RNP binds to the
5' splice site (27) but it is not known whether U1-RNP or other
snRNPs play a role in cleavage at the 5' splice site or in other
steps of the splicing reaction. Fig. 5 shows the results of the
inhibition of the splicing (Fig. 5, lanes 1-3) and the cleavage
(Fig. 5, lanes 4-6) reactions using SLE antisera with anti-Sm
specificity. Preincubation of the extract with normal (Fig. 5,
lanes 2 and 5) and anti-La sera (not shown) had no effect on
cleavage and splicing, whereas anti-Sm serum completely
inhibited the splicing reaction (Fig. 5, lane 3) as well as the
cleavage at the 5' splice site (Fig. 5, lane 6). These data
provide evidence that certain snRNAs are necessary for the
5' splice site cleavage reaction, even when this reaction is
separated from further steps of splicing.
Bam HI Accl
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FIG. 4. Time course of cleavage at the 5' splice site. RNA
truncated 14 nt downstream from the 3' splice site has been
processed for the times indicated and analyzed as in Fig. 2. The
lengths of the input RNA and of the 5' exon-containing fragment are
indicated. C, unprocessed input RNA.
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FIG. 5. Inhibition ofRNA splicing and cleavage by the sera from
SLE patients. The splicing extract was preincubated with the sera
and pretreated extract was then used in the splicing reaction under
standard conditions. RNAs transcribed from the template truncated
with BamHI (lanes 1-3) or Acc I (lanes 4-6) were used in this
experiment. Extract was pretreated with the following: serum from
a healthy individual (lanes 2 and 5) or anti-Sm serum (lanes 3 and 6).
Control unprocessed RNAs are shown in lanes 1 and 4. C, control
serum; N, normal serum. The lengths of the transcripts and of the 5'
exon are indicated on the right.
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DISCUSSION
The experiments presented here describe several important
features of the splicing mechanism. Human P-globin tran-
scripts containing a fragment of the second exon as short as
53 nt were efficiently spliced in a nuclear extract, whereas
transcripts truncated 24 or 14 nt downstream from the 3'
splice site were spliced inefficiently, if at all. All of these
transcripts, however, appeared to be cleaved efficiently and
accurately at the 5' splice site. This was specifically shown
for the transcript terminating 14 nt downstream from the 3'
splice site, which generated two products, one containing
correctly terminated exon 1 and the other containing the 3'
half ofthe RNA carrying the intron in the lariat form. The lack
of splicing of the shortest transcript suggests that either there
is a minimum size requirement of the second exon for splicing
or an important sequence found in this exon has been deleted
in the truncated transcript. Since exon sequences differ from
one another in size and primary sequence, it is very unlikely
that the deletion of specific nucleotides is directly responsible
for our results.
A transcript truncated 54 nt upstream from the 3' splice site
was not cleaved at the 5' splice site, suggesting that 3'-
proximal sequences are required for correct cleavage. Since
this transcript lacks the 3' splice site, the polypyrimidine
stretch, and the lariat branch point, it appears that some or
all of these sequences are required for 5' cleavage. Reed and
Maniatis (16) reported recently that cleavage at the 5' splice
site is blocked by deleting the polypyrimidine stretch and the
3' splice site but not by mutating the AG dinucleotide in the
3' splice site consensus sequence. Therefore, it appears that
the polypyrimidine stretch plays an important role in the
cleavage reaction.
It is interesting that the cofactor optima are the same for
cleavage at the 5' splice site and for the complete splicing
reaction. Some of these cofactors may be required only
during the initial step in splicing. It has been shown that ATP
and Mg2+ are required during the lag period in the in vitro
splicing reaction at the time when presumably a RNP com-
plex is assembled (7). One can then speculate that the actual
processing steps-i.e., cleavage, lariat formation, and final
ligation-may proceed in an "activated" RNP complex
without further involvement of the cofactors.
Previous experiments have shown that splicing can be
inhibited in vitro by anti-U1-RNP and anti-Sm sera, indicat-
ing that snRNPs are involved in this process (18, 19).
However, due to the limitations of the methods used in these
experiments, it was not possible to differentiate between
inhibition of cleavage at the 5' splice site and inhibition of the
subsequent steps of splicing. Results presented in Fig. 5 show
that snRNPs are specifically required for the cleavage reac-
tion at the 5' splice site since anti-Sm IgG inhibited this step.
This result is similar to the effects observed for splicing of
simian virus 40 precursor mRNA in vivo in Xenopus oocytes
(20).
Our results indicate that cleavage at the 5' splice site can
be carried out independent of 3' splice site cleavage and exon
ligation. Truncation of the substrate (shown above), mutation
at the 3' splice site (16), or heat treatment (450C, 30 min) of
the nuclear extract (unpublished data) blocks cleavage at the
3' splice site and exon ligation without affecting the 5' splice
site cleavage step. These results suggest that cleavage at the
5' splice site is carried out by a subset of the factors involved
in splicing. Cleavage at the 5' splice site seems to be quite
complex, as suggested by the requirement for the distal
downstream sequences in the intron, the concomitant for-
mation of the lariat structure, and the requirement for snRNP
components. However, the ability to separate cleavage at the
5' splice site from further steps of mRNA splicing should
simplify more detailed characterization of the splicing mech-
anism.
Note Added in Proof. Since this manuscript was submitted, Ruskin
and Green (28) have reported that a human 8-globin transcript
truncated 14 nucleotides from the 3' splice site is not spliced but is
cleaved at the 5' splice site.
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